Revenue Expectations - NovaBay Pharmaceuticals, Inc. announced preliminary second quarter 2024 net revenue expectations[15] - The company is expected to report significant growth in revenue compared to the previous quarter[15] Business Strategy - NovaBay is focusing on enhancing customer loyalty and satisfaction as part of its business strategy[9] - The company is actively pursuing new revenue sources and market expansion opportunities[9] - NovaBay is engaged in the development of new products and technologies to drive future growth[9] Financial Transparency - The management has indicated that forward-looking statements are subject to risks and uncertainties[9] - The company plans to provide detailed financial results in its upcoming filings[9] - NovaBay is committed to transparency regarding its financial condition and operational results[9] Stakeholder Communication - The press release is intended to inform stakeholders about the company's performance and outlook[15] - The company is classified as an emerging growth company under the Securities Act[14]

NovaBay Pharmaceuticals (NYSEMKT:NBY) stock is falling hard on Thursday after the eyecare and wound care company announced results from its annual shareholder meeting. Included among the proposals in the annual shareholder meeting was a reverse stock split. Traders voted in favor of allowing the company's Board of Directors to enact a reverse split of NBY shares. Following that, NovaBay Pharmaceuticals announced that its Board has approved a one-for-35 reverse stock split for NBY. This will combine 35 share ...

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher." Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ...

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Bruce Voss - LHA, Investor Relations Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalman Edward Woo - Ascendiant Capital Operator Ladies and gentlemen, welcome to the NovaBay Pharmaceuticals Financial Results Conference Call. At this time, all participants are in a listen-only mod ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 68-0454536 ...

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Q4 2023 Earnings Conference Call March 26, 2024 4:30 PM ET Company Participants Jody Cain - LHA, IR Justin Hall - CEO and General Counsel Tommy Law - Interim CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Company Edward Woo - Ascendiant Capital Operator Hello and welcome to the NovaBay Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdic ...

Exhibit 2.1 EXECUTION VERSION MEMBERSHIP UNIT PURCHASE AGREEMENT BY AND AMONG NEW AGE INVESTMENTS LLC, DERMADOCTOR, LLC, AND NOVABAY PHARMACEUTICALS, INC. March 12, 2024 Ta b l e o f C o n t e n t s | A | r | t | i | c | l | e | 1 | D | e | fi | n | i | t | i | o | n | s | 1 | A | r | t | i | c | l | e | 2 | M | e | m | b | e | r | s | h | i | p | U | n | i | t | s | t | o | b | e | P | u | r | c | h | a | s | e | d | 1 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 68-045 ...

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jody Cain - LHA, IR Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Welcome to the NovaBay Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn t ...